13FGuru
Sign in with Google Sign in with Discord

None · None

Arrowhead Pharmaceuticals, Inc. ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.

Sources StockAnalysis company profile stockanalysis.com

Company profile

Business mix

  • Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies.
  • The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials.
  • In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials.
  • The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 0.7% $124.9M 2026-03-31

Recent trading changes over the last 2 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 2 13F filing periods
Net reducers 0 Last 2 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $20.2M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +19.3% +322,021 / 1,670,762
Baker Bros. Advisors 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 30.2% 13F value change +$86.8M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -8.4% 13F value change -$19.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,670,762 Last 2 periods +322,021 (+19.3%) Total shares 1,992,783 Value $124.9M

Recent mentions

No public mentions.